Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYH2085, an orally administered Class 1 new chemical drug designed to inhibit the endonuclease activity of the influenza virus PA protein. Targeted for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above, the candidate has shown broad-spectrum antiviral activity, reductions in viral load and flu-like symptoms in pre-clinical models, along with favourable pharmacokinetics and safety, positioning it as a potentially effective new influenza therapy and strengthening CSPC’s anti-infective drug pipeline.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the research, development and manufacture of innovative drugs, with a growing focus on anti-infective therapies and other specialty treatments for the Chinese and broader global healthcare markets.
Average Trading Volume: 121,701,023
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.5B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.